What happened
In response to pumping out record quarterly results and sharing a slew of upbeat news announcements with investors, shares of Abiomed (NASDAQ: ABMD) , a medical device maker focused on heart recovery, jumped 14.1% in February according to data from S&P Global Market Intelligence .
So what
Abiomed got off to a fast start in February after it reported strong fiscal third-quarter results:
- Revenue grew 34% to $154 million.
- Adjusted net income more than doubled to $32.2 million.
- Adjusted earnings per share of $0.70 were far higher than the $0.51 that Wall Street had expected.
If that wasn't exciting enough, the company also shared two positive regulatory updates with investors later in the month, including:
- Winning FDA approval for a label expansion claim for its Impella heart pumps to treat heart failure associated with cardiomyopathy leading to cardiogenic shock.
- Gaining FDA approval for a label expansion claim for certain Impella heart pumps to be used during elective and urgent high risk percutaneous coronary intervention (PCI) procedures.
Given the upbeat financial results and label expansion wins, it isn't hard to figure out why Abiomed's shares remain on fire.
Now what
Between label expansion claims, product innovations, and international expansion , there are plenty of reasons for investors to believe that Abiomed's days of hyper growth are here to stay. While the company's stock cannot be called cheap right now -- shares are currently trading for more than 22 times sales and 85 times forward earnings -- I still think the long-term potential of this business is so great that the company can continue to put up market-beating results.
10 stocks we like better than Abiomed
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*
David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Abiomed wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of March 5, 2018
Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool recommends Abiomed. The Motley Fool has a disclosure policy .
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
